Meet Dr. Alejandro Magadán
Cerebrovascular Disease and Stroke Specialist in Dallas

As an expert in vascular neurology and neuroimaging, Alejandro Magadán, M.D., of UT Southwestern Medical Center’s Advanced Comprehensive Stroke Center, offers special insight into the use of neuroradiology – particularly magnetic resonance imaging (MRI) – in the acute management of stroke.

“Today’s neuroimaging technologies give us the detailed images and information we need to quickly determine and apply the most appropriate therapies for people who have suffered strokes, as well as those with other cerebrovascular diseases,” he says.

The results can be life changing. Recently, he and his colleagues minimized stroke damage for a patient by using a groundbreaking endovascular procedure – which only a few stroke centers in Texas are qualified to perform. They removed the patient’s blood clot through a procedure that involves catheter-based surgical tools to restore blood flow to the brain.

Dr. Magadán is an expert at integrating state-of-the-art technology with traditional clinical approaches such as a physical exam to get an accurate, comprehensive look at what’s going on with patients before, during, and after treatment.

He notes that with the latest treatments UT Southwestern can offer, people who act quickly when they experience stroke symptoms can better survive – and in many cases, thrive – afterward.

“A lot of people don’t realize that we’re now able to treat many cases of stroke and cerebrovascular disease, not just diagnose them,” he says.

“We offer a wide range of medical therapies, nonsurgical procedures, lifestyle guidance, and, when appropriate, referrals to our experienced neurosurgical colleagues.”

Also active in research, Dr. Magadán is involved in a handful of neurovascular-related studies, including serving as the primary site investigator for a large clinical trial of a new oral blood-thinning drug.

In addition, he is developing a set of questions to help first responders and emergency-room physicians determine the “last time known normal” – crucial information in deciding whether to use “clot-busting” (tPA) drugs in suspected stroke patients.